- Home
- LU vs AAPG Comparison
LU vs AAPG Comparison
Compare LU & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LU | AAPG |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | China | China |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | LU | AAPG |
|---|---|---|
| Price | $2.29 | $23.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $48.40 |
| AVG Volume (30 Days) | ★ 1.4M | 1.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $22.52 | $368.64 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.28 | $17.56 |
| 52 Week High | $4.57 | $48.45 |
Technical Indicators
Market Signals| Indicator | LU | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 31.64 | 47.56 |
| Support Level | N/A | $23.06 |
| Resistance Level | $2.77 | $26.01 |
| Average True Range (ATR) | 0.09 | 0.93 |
| MACD | -0.04 | 0.13 |
| Stochastic Oscillator | 1.50 | 62.79 |
Price Performance
Historical ComparisonAbout LU Lufax Holding Ltd each representing two (2)
Lufax Holding Ltd is a technology-empowered personal financial services platform in China. The company address the large unmet demand for personal lending among small business owners as well as salaried workers in China and provides tailor-made wealth management solutions to China's middle class and affluent population. Its platform has two hubs namely Retail Credit Facilitation Hub and Wealth Management Hub.
About AAPG Ascentage Pharma Group International American Depository Shares
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.